Tr1X Inc. develops allogeneic engineered Tr1 Treg cell therapies to restore immune tolerance in patients with treatment-refractory autoimmune and inflammatory diseases, such as Crohn’s disease. Their proprietary platform generates stable, long-lived regulatory T cells that modulate immune responses and induce de-novo Tr1 cells at sites of inflammation.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Many patients with autoimmune and inflammatory diseases, such as Crohn's disease, do not respond to existing treatments, leaving them with limited options to manage their conditions. Current therapies often fail to restore immune tolerance, leading to chronic inflammation and disease progression.
Solution
Tr1X is developing allogeneic engineered Tr1 regulatory T cell (Treg) therapies designed to restore immune homeostasis in patients with treatment-refractory autoimmune and inflammatory diseases. Their approach leverages genetically engineered T cells to mimic the function of naturally occurring Type 1 regulatory T (Tr1) cells, a subset of regulatory cells crucial for immune tolerance. The engineered Tr1 cells are designed to suppress immune responses locally at sites of inflammation while preserving protective immunity. These cells are stable and long-lived, even in inflammatory environments, and can induce de-novo Tr1 cells, further modulating effector cell responses.
Target Audience
The primary target audience includes patients with treatment-refractory autoimmune and inflammatory diseases, such as Crohn's disease, and the physicians who treat them.
Features
- Allogeneic engineered Tr1 Treg cell therapy for off-the-shelf use
- Genetically engineered T cells designed to mimic naturally occurring Tr1 cells
- Targeted and localized immune suppression at sites of inflammation
- Preservation of protective immune responses
- High stability and low plasticity of engineered cells in inflammatory environments
- Induction of de-novo Tr1 cells to further modulate immune responses